Following hot on the heels of October’s 3Q24 trading update, Shield has announced the completion of recruitment of the China Phase 3 study in adult patients with inflammatory bowel disease (IBD) and Iron Deficiency Anaemia (IDA). Investors will recall that this confirmatory study is co-sponsored with Shield’s partner in China, and today’s news means regulatory NDA filing in China is expected in 2025, with the potential to significantly increase the global availability of ACCRUFeR®/FeRACRRU® assu ....
